Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Google Secures Pentagon AI Deal for Classified Projects 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
South Korean biotech company Celltrion Inc. plans to merge with its two affiliates, Celltrion Healthcare Co. and Celltrion Pharma Inc., to establish a holding company structure by the end of 2021.
Celltrion Group Chairman Seo Jung-jin would establish Celltrion Healthcare Holdings by investing his stakes in Celltrion Healthcare, making the holding company its largest shareholder.
Celltrion Group Chairman Seo Jung-Jin would hold 11.21 percent in Celltrion Healthcare Holdings, which in turn would have a 24.33 percent stake.
The process would be hastened when requirements for relevant laws regarding anti-monopoly and fair trade are met.
Seo noted that the merger would depend upon the wishes of shareholders.
Celltrion is conducting phase one clinical trials on patients of its coronavirus treatment, CT-P59, to evaluate the safety and efficacy of the treatment.
